Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3Â days of treatment: Relation to coagulation factors and thrombin generation

Plasma fibrin clot properties in AF patients are favourably modified as early as after 3 days of VKA administration, which might contribute to antithrombotic effectiveness.